HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort
暂无分享,去创建一个
Julio S. G. Montaner | Michael V. O'Shaughnessy | P. Harrigan | C. Alexander | J. Montaner | M. O’Shaughnessy | W. Dong | P. Richard Harrigan | Winnie Dong | Theresa Mo | Christopher S. Alexander | Keith Chan | Nathalie Jahnke | Magdalena A. Piaseczny | T. Mo | Keith J. Chan | N. Jahnke | M. O'shaughnessy
[1] J. Kahn,et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. , 1998, The New England journal of medicine.
[2] B Clotet,et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. , 1998, JAMA.
[3] S. Hammer,et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. , 1996, JAMA.
[4] E. Rosenberg,et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. , 1999, JAMA.
[5] D. Kuritzkes,et al. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients , 1996, AIDS.
[6] P. Klenerman,et al. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. , 1994, The Journal of infectious diseases.
[7] R de Boer,et al. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215 , 1997, Journal of virology.
[8] B. Larder,et al. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing , 1993, Nature.
[9] John W. Mellors,et al. A Novel Polymorphism at Codon 333 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Can Facilitate Dual Resistance to Zidovudine and l-2′,3′-Dideoxy-3′-Thiacytidine , 1998, Journal of Virology.
[10] S. Yerly,et al. Transmission of antiretroviral-drug-resistant HIV-1 variants , 1999, The Lancet.
[11] J. Mascola,et al. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel , 2000, AIDS.
[12] J. Montaner,et al. Primary lamivudine resistance in acute/early human immunodeficiency virus infection. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] N. Shen,et al. Extensive polymorphisms observed in HIV–1 clade B protease gene using high–density oligonucleotide arrays , 1996, Nature Medicine.
[14] M. Wainberg,et al. Public health implications of antiretroviral therapy and HIV drug resistance. , 1998, JAMA.
[15] G. Moyle. Current knowledge of HIV-1 reverse transcriptase mutations selected during nucleoside analogue therapy: the potential to use resistance data to guide clinical decisions. , 1997, The Journal of antimicrobial chemotherapy.
[16] M A Wainberg,et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use , 2000, AIDS.
[17] B. Larder,et al. Mutations in Retroviral Genes Associated with Drug Resistance , 1996 .
[18] Douglas D. Richman,et al. Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel , 1996 .
[19] P. Harrigan,et al. Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine. , 2000, The Journal of infectious diseases.
[20] B. Larder,et al. Viral resistance and the selection of antiretroviral combinations. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[21] R. Schinazi,et al. Antiviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase occur in specific RNA structural regions , 1994, Antimicrobial Agents and Chemotherapy.
[22] D. Richman,et al. Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy , 2000, AIDS.
[23] M. Mouroux,et al. Polymorphism of the Human Immunodeficiency Virus Type 1 (HIV-1) Protease Gene and Response of HIV-1-Infected Patients to a Protease Inhibitor , 1999, Journal of Clinical Microbiology.
[24] S. Little. Transmission and Prevalence of HIV Resistance among Treatment-Naive Subjects , 2000, Antiviral therapy.
[25] P. Harrigan,et al. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility , 1996, Journal of virology.
[26] C. Boucher,et al. First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, The Netherlands. , 1996, AIDS.
[27] Bradley J. Betts,et al. Human immunodeficiency virus reverse transcriptase and protease sequence database. , 2003, Nucleic acids research.
[28] F. McCutchan,et al. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. , 1993, The New England journal of medicine.
[29] Tom de Groot,et al. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. , 1997, The Journal of infectious diseases.
[30] P. Massip,et al. Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV‐1 infection , 2000, Journal of medical virology.
[31] P. Harrigan,et al. Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users. , 1999, AIDS.
[32] D. Stuart,et al. A Family of Insertion Mutations between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog Resistance , 1999, Antimicrobial Agents and Chemotherapy.
[33] R. Pon,et al. Rapid DNA fingerprinting to control for specimen errors in HIV testing by the polymerase chain reaction. , 1992, Molecular and cellular probes.
[34] D. Cooper,et al. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. , 1997, The Journal of infectious diseases.